Precision BioSciences Receives Notice of Intent to Grant for New European Patent Covering Engineered Meganucleases
2/14/2012 6:49:41 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the European Patent Office (EPO) has issued a notification of Intent to Grant for European Patent Application No. 10 191 888 (“the '888 Application”). The thirteen allowed claims relate to both engineered meganucleases and methods for utilizing the engineered meganucleases for the production of genetically modified cells and organisms. These methods also include uses of engineered meganucleases as a therapeutic and are an important component of Precision’s Directed Nuclease Editor (DNE) genome engineering technology.
comments powered by